AK152 is the first bispecific antibody developed in China for disease-modifying therapy in Alzheimer's Disease, marking a significant breakthrough in the field. Furthermore, it is Akeso's first innovative therapeutic candidate designed to target the central nervous system (CNS). This achievement underscores a critical milestone in expanding Akeso's research and development pipeline into neurodegenerative diseases and positions the company to strengthen its presence as a globally comprehensive pharmaceutical ...